EHA 2018 | Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, presented preliminary data from the Phase II CAPTIVATE trial (NCT02910583) at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial combined ibrutinib and venetoclax in the frontline treatment of chronic lymphocytic leukemia (CLL), with the aim of yielding deeper responses than current standard therapies. Dr Ghia discusses the promising data from the trial, with 86% of patients reaching MRD negativity, and the treatment being as well tolerated as standard monotherapies.
Get great new content delivered to your inboxSign up